Terms: = Endocrine gland cancer AND SUFU, RP11-47A8_1, 51684, ENSG00000121410, PRO1280, SUFUXL, Q9UMX1, SUFUH AND Treatment
31529 results:
1. Genome-wide loss of heterozygosity predicts aggressive, treatment-refractory behavior in pituitary neuroendocrine tumors.
Lin AL; Rudneva VA; Richards AL; Zhang Y; Woo HJ; Cohen M; Tisnado J; Majd N; Wardlaw SL; Page-Wilson G; Sengupta S; Chow F; Goichot B; Ozer BH; Dietrich J; Nachtigall L; Desai A; Alano T; Ogilive S; Solit DB; Bale TA; Rosenblum M; Donoghue MTA; Geer EB; Tabar V
Acta Neuropathol; 2024 May; 147(1):85. PubMed ID: 38758238
[TBL] [Abstract] [Full Text] [Related]
2. Intelligent nanovesicle for remodeling tumor microenvironment and circulating tumor chemoimmunotherapy amplification.
Huai M; Wang Y; Li J; Pan J; Sun F; Zhang F; Zhang Y; Xu L
J Nanobiotechnology; 2024 May; 22(1):257. PubMed ID: 38755645
[TBL] [Abstract] [Full Text] [Related]
3. Niraparib, Dostarlimab, and Bevacizumab as Combination Therapy in Pretreated, Advanced Platinum-Resistant Ovarian cancer: Findings From Cohort A of the OPAL Phase II Trial.
Liu JF; Gaillard S; Wahner Hendrickson AE; Yeku O; Diver E; Gunderson Jackson C; Arend R; Ratner E; Samnotra V; Gupta D; Chung J; Zhang H; Compton N; Baines A; Bacqué E; Liu X; Felicetti B; Konecny GE
JCO Precis Oncol; 2024 May; 8():e2300693. PubMed ID: 38754056
[TBL] [Abstract] [Full Text] [Related]
4. Shikonin reduces M2 macrophage population in ovarian cancer by repressing exosome production and the exosomal galectin 3-mediated β-catenin activation.
Wang M; Sun Y; Gu R; Tang Y; Han G; Zhao S
J Ovarian Res; 2024 May; 17(1):101. PubMed ID: 38745186
[TBL] [Abstract] [Full Text] [Related]
5. Impact on Long-term Survival of a Standardized Histopathological Protocol on the R1 Incidence in Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma.
Moiş E; Graur F; Puia C; Vlad I; Moldovan S; Ursu CP; Nechita VI; Vălean D; Furcea L; Puia A; Zaharie F; Popa C; Bodea R; Iancu C; Rusu I; Hajjar NA
Chirurgia (Bucur); 2024 Apr; 119(2):171-183. PubMed ID: 38743830
[No Abstract] [Full Text] [Related]
6. [treatment strategy for low-risk papillary thyroid carcinoma with diameter smaller than 1 cm: immediate surgery vs active surveillance].
Sun W; Liu Q; Zhang H
Zhonghua Yi Xue Za Zhi; 2024 May; 104(18):1572-1577. PubMed ID: 38742343
[TBL] [Abstract] [Full Text] [Related]
7. MKLN1-AS promotes pancreatic cancer progression as a crucial downstream mediator of HIF-1α through miR-185-5p/TEAD1 pathway.
Chen J; Li L; Feng Y; Zhao Y; Sun F; Zhou X; Yiqi D; Li Z; Kong F; Kong X
Cell Biol Toxicol; 2024 May; 40(1):30. PubMed ID: 38740637
[TBL] [Abstract] [Full Text] [Related]
8. The influence of delayed gastric emptying on quality of life after partial duodenopancreatectomy.
Klein M; Warschkow R; Ukegjini K; Krstic D; Burri P; Chatziisaak D; Steffen T; Schmied B; Probst P; Tarantino I
Langenbecks Arch Surg; 2024 May; 409(1):155. PubMed ID: 38727871
[TBL] [Abstract] [Full Text] [Related]
9. A Competing Risk Nomogram for Prediction of Prognosis in Patients With Primary Squamous Cell Thyroid Carcinoma.
Tian Y; He L; Zhang B; Deng L; Wang J
Technol Cancer Res Treat; 2024; 23():15330338241254059. PubMed ID: 38725285
[No Abstract] [Full Text] [Related]
10. Genomic Profiling of Rare Undifferentiated Sarcomatoid Subtypes of Pancreatic Carcinomas: In Search of Therapeutic Targets.
Faber EB; Krause HB; Amin K; Walker P; Hosein PJ; Shields AF; Lenz HJ; Prakash A; Goel S; Oberley M; Malleo G; Luchini C; Hwang J; Florou V; Garrido-Laguna I; Lou E
JCO Precis Oncol; 2024 May; 8():e2300595. PubMed ID: 38723231
[TBL] [Abstract] [Full Text] [Related]
11. Preoperative peripheral inflammatory markers are predictors of postoperative central diabetes insipidus in craniopharyngioma patients: a retrospective study.
Wang J; Wang G; Cheng L; Zhu H; Wang J; Ding X; Niu H; Zhao K; Shu K
BMC Cancer; 2024 May; 24(1):572. PubMed ID: 38720306
[TBL] [Abstract] [Full Text] [Related]
12. [Analysis of factors affecting the prognosis of patients with pancreatic cancer patients with obstructive jaundice].
Zhang L; Li M; Sun QF; Yu HP
Zhonghua Nei Ke Za Zhi; 2024 May; 63(5):474-479. PubMed ID: 38715484
[No Abstract] [Full Text] [Related]
13. Overweight as a biomarker for concomitant thyroid cancer in patients with Graves' disease.
Park J; An S; Bae JS; Kim JS; Kim K
Front Endocrinol (Lausanne); 2024; 15():1382124. PubMed ID: 38711981
[TBL] [Abstract] [Full Text] [Related]
14. treatment strategies for borderline resectable pancreatic neuroendocrine tumors: a narrative review.
Chang JY; Ruff SM; Cloyd JM
Chin Clin Oncol; 2024 Apr; 13(2):25. PubMed ID: 38711178
[TBL] [Abstract] [Full Text] [Related]
15. Active surveillance is a feasible and safe strategy in selected patients with papillary thyroid cancer and suspicious cervical lymph nodes detected after thyroidectomy.
Solórzano M; Lustig N; Mosso L; Espinoza M; Santana R; Gonzalez H; Montero PH; Cruz F; Solar A; Domínguez JM
Arch Endocrinol Metab; 2024 May; 68():e230146. PubMed ID: 38709151
[TBL] [Abstract] [Full Text] [Related]
16. The prophylactic antiemetic therapies in management of differentiated thyroid cancer patients with radioactive iodine therapy: a single-center, non-randomized clinical trial.
Li X; Cao J; Wang W; Zhu X; Sun Y; Song L; Zhang W; Han Y
Front Endocrinol (Lausanne); 2024; 15():1310223. PubMed ID: 38706697
[TBL] [Abstract] [Full Text] [Related]
17. Perioperative management of a patient with unexpectedly detected early-stage ovarian mucinous carcinoma combined with progressive bulbar paralysis: a case report and literature review.
Zhang D; Xu R; Huo T; Liu Y; Hao Z; Sun Y; Xi X; Du X; Wang L; Du J
BMC Womens Health; 2024 May; 24(1):274. PubMed ID: 38704534
[TBL] [Abstract] [Full Text] [Related]
18. Comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in patients with newly diagnosed homologous recombination-deficient stage III/IV ovarian cancer: study protocol for cohort C of the open-label, phase 2, randomized controlled multicenter OPAL trial.
Belotte J; Felicetti B; Baines AJ; YoussefAgha A; Rojas-Espaillat L; Ortiz AG; Provencher D; Vázquez RM; Cortijo LG; Zeng X
Trials; 2024 May; 25(1):301. PubMed ID: 38702828
[TBL] [Abstract] [Full Text] [Related]
19. Efficacy and safety of PD-1/PD-L1 immune checkpoint inhibitors in the treatment of recurrent ovarian cancer: A systematic review and meta-analysis.
Chen Y; Liu X; Hu Y; Xia L
Medicine (Baltimore); 2024 May; 103(18):e38019. PubMed ID: 38701316
[TBL] [Abstract] [Full Text] [Related]
20. Incidentally detected follicular thyroid carcinoma mimicking parathyroid adenoma on Tc-99m MIBI scan: A case report.
Han YH; Jeong HJ; Lee SY; Lim ST
Medicine (Baltimore); 2024 May; 103(18):e38107. PubMed ID: 38701245
[TBL] [Abstract] [Full Text] [Related]
[Next]
